This is a simplified view: Sign up or Log in to access full view.


Lab-on-Chip based Diagnostic System for Biomolecular analysis

A diagnostic system (RealLoC), whose feasibility was already demonstrated (TRL=5), should be brought at a higher level of development (TRL=7), by increasing reliabilty, studying better micro and nanomaterials, clinical protocols to be applied in a Lab-on-Chip based portable instruments.

Foto de

Published by @livio_cognolato
29 Feb 2016


Show/Hide specialization/thematic fields

 

Share this page K


Project description

Early detection of cancer biomarkers is of huge importance to defeat, or at least reduce effects of one of the main cause of
death. Population ageing in Europe makes this point even more urgent. Current practice of screening or post-treatment
check of new biomarkers, based on testing in centralized clinical labs is costly and sometimes uncomfortable for people
living far from hospitals. Point-of-Care (PoC) approach appears to be an effective way to perform single analysis at low cost,
thanks to IT technologies allowing transfer of data to a remote medical center which elaborates results and makes diagnosis.
For instance, post-treatment control of patients requires frequent tests, and quantitative biomarkers determination.
Molecular Biology tests are well established in clinical labs, both “end-point” and quantitative (qPCR), but at our knowledge a
qPCR instrument, automated and based on Lab-on-Chip (LoC) technology, suitable for PoC is not yet marketed. Recently,
we have designed and realized an automated prototype, RealLoC, and have validated qPCR protocol on LoC, finalized to
measure the amount of clinical biomarkers of Colon Rectum Carcinoma in whole blood. A preliminary clinical validation in a
public hospital laboratory was performed on real patient blood samples, both retrospective than prospective, showing results
in excellent accordance with common techniques. The RealLoC represents a disruptive approach to early detection
screening and post-treatment test of traditional and novel genomic biomarkers, based on presence of mutated nucleic acids.
Our objectives are: to engineer a more reliable version of the platform; to plan the clinical validation of different biomarkers,
selected by list of available materials from hospital repository; investigating in depth market opportunities, through a survey
among opinion leaders and potential market evaluation.

Project abstract

A diagnostic system (RealLoC), whose feasibility was already demonstrated (TRL=5), should be brought at a higher level of development (TRL=7), by increasing reliabilty, studying better micro and nanomaterials, clinical protocols to be applied in a Lab-on-Chip based portable instruments.

Consortia

1. Coordinator: An Italian SME, settled in Piemonte (nort-west Italy, a Region associated to INCOMERA program). The SME is specialized in design of molds and injction molding of disposable biomedical devices. The SME has developed the prototype system in association with local academic partner.
2. University of Torino, School of Medicine has developed the biological protocol which has been implemented in the system, and has carried out the pre-clinical validation in a Hospital laboratory, comparing the RealLoC to standard systems and getting excellent results.
3. Looking for a SME from one of teh INCOMERA regions. The role is including (but not limited to) electronics, firmware and GUI development, ICT applications, etc.

Participant



SMEs



Europe
Spain
Belgium
Germany
All INCOMERA regions